Anterior Segment Herpetic Keratitis
1. Biser S, Perry H, Herpes simplex keratitis. Ophthalmic Hyperguide: Corneal and Anterior Segment Diseases, 2007. Available at:
www.ophthalmic.hyperguides.com (accessed January 6, 2011).
2. Tabbara KF, Al Balushi N, Topical ganciclovir in the treatment of acute herpetic keratitis, Clin Ophthalmol, 2010;4:905–12.
3. Muller WJ, Jones CA, Koelle DM, Immunobiology of herpes simplex virus and cytomegalovirus infections of the fetus and newborn, Curr Immunol Rev, 2010;6:38–55.
4. Isacsohn M, Smetana Z, Rones ZZ, et al., A sero-epidemiological study of herpes virus type 1 and 2 infection in Israel, J Clin Virol, 2002;24:85–92.
5. Smith JS, Robinson NJ, Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review, J Infect Dis, 2002;186(Suppl. 1):S3–28.
6. Xu F, Schillinger JA, Sternberg MR, et al., Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994, J Infect Dis, 2002;185:1019–24.
7. TJ, Epidemiology and natural history of ocular herpes simplex virus infection in Rochester, Minnesota, 1950-1982, Trans Am Ophthalmol Soc, 1988;86:688–724.
8. Colin J, Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes, Clin Ophthalmol, 2007;1:441–53.
9. El Hayderi L, Raty L, Failla V, et al., Severe herpes simplex virus type-I infections after dental procedures, Med Oral Patol Oral Cir Bucal, 2011;16:e15–8.
10. Elftman MD, Hunzeker JT, Mellinger JC, et al., Stress-induced glucocorticoids at the earliest stages of herpes simplex virus-1 infection suppress subsequent antiviral immunity, implicating impaired dendritic cell function, J Immunol, 2010;184:1867–75.
11. Liesegang TJ, Melton LJ, 3rd, Daly PJ, et al., Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982, Arch Ophthalmol, 1989;107:1155–9.
12. Wilhelmus KR, The treatment of herpes simplex virus epithelial keratitis, Trans Am Ophthalmol Soc, 2000;98:505–32.
13. Darougar S, Wishart MS, Viswalingam ND, Epidemiological and clinical features of primary herpes simplex virus ocular infection, Br J Ophthalmol, 1985;69:2–6.
14. Liesegang TJ, Herpes simplex virus epidemiology and ocular importance, Cornea, 2001;20:1–13.
15. Wilhelmus KR, Therapeutic interventions for herpes simplex virus epithelial keratitis, Cochrane Database Syst Rev, 2007;CD002898.
16. De Kesel RJ, Koppen C, Ieven M, et al., Primary graft failure caused by herpes simplex virus type 1, Cornea, 2001;20:187–90.
17. Kaufman H, Ganciclovir: a promising topical antiviral gel for herpetic keratitis, Expert Review of Ophthalmology, 2009;4:367–75.
18. la Lau C, Oosterhuis JA, Versteeg J, et al., Aciclovir and trifluorothymidine in herpetic keratitis. Preliminary report of a multicentered trial, Doc Ophthalmol, 1981;50:287–90.
19. Majumdar S, Tirucherai GS, Pal D, et al., Functional differences in nucleoside and nucleobase transporters expressed on the rabbit corneal epithelial cell line (SIRC) and isolated rabbit cornea, AAPS PharmSci, 2003;5:E15.
20. Maudgal PC, Van Damme B, Missotten L, Corneal epithelial dysplasia after trifluridine use, Graefes Arch Clin Exp Ophthalmol, 1983;220:6–12.
21. Au E, Sacks SL, Therapeutic Options for Herpes Simplex Infections, Curr Infect Dis Rep, 2003;5:22–7.
22. Hoh HB, Hurley C, Claoue C, et al., Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study, Br J Ophthalmol, 1996;80:140–3.
23. Tilson HH, Engle CR, Andrews EB, Safety of acyclovir: a summary of the first 10 years experience, J Med Virol, 1993;Suppl 1:67–73.
24. Whitley RJ, Roizman B, Herpes simplex virus infections, Lancet, 2001;357:1513–8.
25. Cantell K, Development of antiviral therapy with alpha interferons: promises, false hopes and accomplishments, Ann Med, 1995;27:23–8.
26. Colin J, Chastel C, Renard G, et al., Combination therapy for dendritic keratitis with human leukocyte interferon and acyclovir, Am J Ophthalmol, 1983;95:346–8.
27. de Koning EW, van Bijsterveld OP, Cantell K, Combination therapy for dendritic keratitis with acyclovir and alpha- interferon, Arch Ophthalmol, 1983;101:1866–8.
28. Sundmacher R, Cantell K, Mattes A, Combination therapy for dendritic keratitis, High-titer alpha-interferon and trifluridine, Arch Ophthalmol, 1984;102:554–5.
29. Colin J, Hoh HB, Easty DL, et al., Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis, Cornea, 1997;16:393–9.
30. Tabbara KF, Pharmacologic strategies in the prevention and treatment of corneal transplant rejection, Int Ophthalmol, 2008;28:223–32.
31. Greco A, Diaz JJ, Thouvenot D, et al., Novel targets for the development of anti-herpes compounds, Infect Disord Drug Targets, 2007;7:11–8.
32. Levin MJ, Bacon TH, Leary JJ, Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients, Clin Infect Dis, 2004;39 Suppl 5:S248–57.
33. Ozkan B, Elibol O, Yuksel N, et al., Why do patients with improved visual acuity drop out of RGP contact lens use? Ten-year follow-up results in patients with scarred corneas, Eur J Ophthalmol, 2009;19:343–7.
34. Cobo LM, Coster DJ, Rice NS, et al., Prognosis and management of corneal transplantation for herpetic keratitis, Arch Ophthalmol, 1980;98:1755–9.
35. Arentsen JJ, Laibson PR, Cohen EJ, Management of corneal descemetoceles and perforations, Trans Am Ophthalmol Soc, 1984;82:92–105.
36. Shi W, Chen M, Xie L, Amniotic membrane transplantation combined with antiviral and steroid therapy for herpes necrotizing stromal keratitis, Ophthalmology, 2007;114:1476–81.
37. Cheng YC, Grill SP, Dutschman GE, et al., Metabolism of 9-(1,3- dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells, J Biol Chem, 1983a;258:12460–4.
38. Naesens L, Lenaerts L, Andrei G, et al., Antiadenovirus activities of several classes of nucleoside and nucleotide analogues, Antimicrob Agents Chemother, 2005;49:1010–6.
39. Freitas VR, Smee DF, Chernow M, et al., Activity of 9-(1,3- dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses, Antimicrob Agents Chemother, 1985;28:240–5.
40. Matthews T, Boehme R, Antiviral activity and mechanism of action of ganciclovir, Rev Infect Dis, 1988;10 Suppl 3:S490–4.
41. Hamzeh FM, Lietman PS, Gibson W, et al., Identification of the lytic origin of DNA replication in human cytomegalovirus by a novel approach utilizing ganciclovir-induced chain termination, J Virol, 1990;64:6184–95.
42. Elion GB, The biochemistry and mechanism of action of acyclovir, J Antimicrob Chemother, 1983;12 Suppl B:9–17.
43. Biron KK, Stanat SC, Sorrell JB, et al., Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-
(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus, Proc Natl Acad Sci U S A, 1985;82:2473–7.
44. St Clair MH, Miller WH, Miller RL, et al., Inhibition of cellular alpha DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U, Antimicrob Agents Chemother, 1984;25:191–4.
45. Cheng YC, Huang ES, Lin JC, et al., Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1, Proc Natl Acad Sci U S A, 1983b;80:2767–70.
46. Athmanathan S, Garg P, Rao GN, Ophthalmic antiviral chemotherapy: an overview, Indian J Ophthalmol, 1997;45:203–10.
47. Inoue Y, Ohashi Y, Shimomura Y, et al., Comparative efficacy of three antiviral drugs in mice herpetic keratitis, Jpn J Ophthalmol, 1989;33:125–31.
48. Shaw MM, Gurr WK, Watts PA, et al., Ganciclovir and penciclovir, but not acyclovir, induce apoptosis in herpes simplex virus thymidine kinase-transformed baby hamster kidney cells, Antivir Chem Chemother, 2001;12:175–86.
49. Shiota H, Naito T, Mimura Y, Anti-herpes simplex virus (HSV) effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in rabbit cornea, Curr Eye Res, 1987;6:241–5.
50. Trousdale MD, Nesburn AB, Willey DE, et al., Efficacy of BW759 (9-[[2-hydroxy-1(hydroxymethyl)ethoxy]methyl]guanine) against herpes simplex virus type 1 keratitis in rabbits, Curr Eye Res, 1984;3:1007–15.
51. Castela N, Vermerie N, Chast F, et al., Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy, J Ocul Pharmacol, 1994;10:439–51.
52. Tabbara KF, Treatment of herpetic keratitis, Ophthalmology, 2005;112:1640.
53. HEDS, Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Herpetic Eye Disease Study Group, Arch Ophthalmol, 2000;118:1030–6.
54. Trousdale MD, Goldschmidt PL, Nobrega R, Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes, Cornea, 1994;13:435–9.
55. Taylor DL, Jeffries DJ, Taylor-Robinson D, et al., The susceptibility of adenovirus infection to the anti-cytomegalovirus drug, ganciclovir (DHPG), FEMS Mircobiol Lett, 1998;49:337–41.
56. Tabbara KF, Jarade EF, Ganciclovir effects in adenoviral keratoconjunctivitis, IOVS, 2001;42(4):S579.
57. Verin PH, Mortemousque B, Barach D, Ganciclovir 0.15% gel, a new treatment in epidemic jeratoconjunctivitis (EKC), Ophthalmic Res, 1997;29(Suppl. 1):12–27.
58. Bruno B, Gooley T, Hackman RC, et al., Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival, Biol Blood Marrow Transplant, 2003;9:341–52.
59. Gordon YJ, Romanowski E, Araullo-Cruz T, et al., Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2’-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro, Antiviral Res, 1991;16:11–6.
60. Kinchington PR, Romanowski EG, Jerold Gordon Y, Prospects for adenovirus antivirals, J Antimicrob Chemother, 2005;55:424–9.
61. Schonberger S, Meisel R, Adams O, et al., Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 2010;16:1428–35.
62. Baker, FDA approves oral ganciclovir as first drug to prevent CMV disease. US FDA National Library of Medicine AIDSline, Beta, 1995.
63. Chee SP, Jap A, Cytomegalovirus anterior uveitis: outcome of treatment, Br J Ophthalmol, 2010;94:1648–52.
64. Chau Tran TH, Cassoux N, Bodaghi B, et al., Successful treatment with combination of systemic antiviral drugs and intravitreal ganciclovir injections in the management of severe necrotizing herpetic retinitis, Ocul Immunol Inflamm, 2003;11:141–4.
65. Kim SJ, Equi R, Belair ML, et al., Long-term preservation of vision in progressive outer retinal necrosis treated with combination antiviral drugs and highly active antiretroviral therapy, Ocul Immunol Inflamm, 2007;15:425–7.
65. Tam PM, Hooper CY, Lightman S, Antiviral selection in the management of acute retinal necrosis, Clin Ophthalmol, 2010;4:11–20.
68
US OPHTHALMIC REVIEW
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116